You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. Stocks
  2. SELLAS Life Sciences Group Inc
  3. Swot
swot-logo

SELLAS Life Sciences Group Inc SWOT Analysis: Strengths, Weakness, Opportunity, and Threats

SELLAS Life Sciences Group Inc has 18 Strengths, 5 Weaknesses, 3 Opportunities and 1 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential

Add SWOT widget to your site/app

Rising Momentum: Momentum Score Weekly Gainers

Companies with 10% increase in share price over three months, with rising net profit growth

Strong Momentum: Price above short, medium and long term moving averages

Relative Outperformance versus Industry over 1 Week

Significant (over 30%) distance from 52 week high

Relative Outperformance versus Industry over 1 Month

Rising Net Cash Flow and Cash from Operating activity

Relative Outperformance versus Industry over the Quarter (3 Months)

Relative Outperformance versus Industry over 1 Year

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Annual Net Profits improving for last 2 years

Increasing profits every quarter for the past 3 quarters

Stock with Low PE (PE < = 10)

Stocks Outperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years

Top Losers

Low Piotroski Score : Companies with weak financials

Top Losers

Forecaster Consensus Estimates: Stocks with Strong Buy Calls from Analysts

Institutions increasing their shareholding

MFs increased their shareholding last quarter

Mutual Funds Decreased Shareholding in Past Month

Promoters increasing shareholding QoQ

Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks